doi:10.3969/j.issn.1673-8640.2021.09.021

Abstract

CLC Number:

R446.1

Figures/Tables 4

References 11

[1]	CHEN T K, KNICELY D H, GRAMS M E. Chronic kidney disease diagnosis and management:a review[J]. JAMA, 2019, 322(13):1294-1304. DOI URL
[2]	上海慢性肾脏病早发现及规范化诊治与示范项目专家组. 慢性肾脏病筛查诊断及防治指南[J]. 中国实用内科杂志, 2017, 37(1):28-34.
[3]	DELANAYE P, JAGER K J, BÖKENKAMP A, et al. CKD:a call for an age-adapted definition[J]. J Am Soc Nephrol, 2019, 30(10):1785-1805. DOI URL
[4]	伊双燕, 骆雷鸣, 付士辉, 等. 高龄严重急性失代偿性心力衰竭患者发生肾功能恶化的影响因素分析及肾功能恶化对其预后的预测价值研究[J]. 中国全科医学, 2018, 21(18):2167-2172.
[5]	CAO Z, JIA Y, ZHU B. BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic medicine[J]. Int J Mol Sci, 2019, 20(8):1820. DOI URL
[6]	TEO B W, ZHANG L, GUH J Y, et al. Glomerular filtration rates in Asians[J]. Adv Chronic Kidney Dis, 2018, 25(1):41-48. DOI URL
[7]	GROMADZINSKI L, JANUSZKO-GIERGIELEWICZ B, CZARNACKA K, et al. NT-proBNP in the prognosis of death or need for renal replacement therapy in patients with stage 3-5 chronic kidney disease[J]. Cardiorenal Med, 2019, 9(2):125-134. DOI URL
[8]	PETRA E, ZOIDAKIS J, VLAHOU A. Protein biomarkers for cardiorenal syndrome[J]. Expert Rev Proteomics, 2019, 16(4):325-336. DOI URL
[9]	CHARMETANT X, PECQUET M, POIRIÉ P, et al. Impact of age and renal function on usefulness of NT-proBNP to diagnose heart failure[J]. Clin Nephrol, 2019, 92(2):65-72. DOI URL
[10]	BANSAL N, ZALNICK L, SHLPAK M G, et al. Cardiac and stress biomarkers and chronic kidney disease progression:the CRIC study[J]. Clin Chem, 2019, 65(11):1448-1457. DOI URL
[11]	GAO P, ZHU Q, BIAN S, et al. Prognostic value of plasma NT-proBNP levels in very old patients with moderate renal insufficiency in China[J]. Z Gerontol Geriatr, 2018, 51(8):889-896. DOI URL

组别	例数	CKD病程/年	LVEF/%	SV/mL	SCr/ （μmol/L）	Cys C/ （mg/L）	NT-proBNP / （pg/mL）
正常对照组	50		57.22±5.14	63.78±5.54	92.21±21.09	0.78±0.12	737.62±520.17
CKD无CHF组	66	6.85±3.12	50.93±5.65^*	54.93±5.45^*	332.18±45.79^*	1.66±0.38^*	1 224.32±688.92^*
CKD合并CHF 组	54	7.02±3.68	41.31±4.24^*#	51.31±5.08^*#	554.56±42.33^*#	2.97±0.45^*#	2 144.50±654.33^*#
统计值		1.10	156.20	83.48	1 831.28	581.13	78.74
P值		0.335	<0.001	<0.001	<0.001	<0.001	<0.001

组别	例数	CKD病程/年	LVEF/%	SV/mL	SCr/ （μmol/L）	Cys C/ （mg/L）	NT-proBNP / （pg/mL）
正常对照组	50		57.22±5.14	63.78±5.54	92.21±21.09	0.78±0.12	737.62±520.17
CKD无CHF组	66	6.85±3.12	50.93±5.65^*	54.93±5.45^*	332.18±45.79^*	1.66±0.38^*	1 224.32±688.92^*
CKD合并CHF 组	54	7.02±3.68	41.31±4.24^*#	51.31±5.08^*#	554.56±42.33^*#	2.97±0.45^*#	2 144.50±654.33^*#
统计值		1.10	156.20	83.48	1 831.28	581.13	78.74
P值		0.335	<0.001	<0.001	<0.001	<0.001	<0.001

CKD分期	例数	SCr/（μmol/L）	Cys C/（mg/L）	NT-proBNP/（pg/mL）
CKD1期	18	101.34±26.92	1.01±0.21	675.61±381.73
CKD2~3期	15	345.56±22.83^*	1.64±0.28^*	1 133.17±433.56^*
CKD4~5期	21	626.83±34.05^*#	2.75±0.38^*#	1 525.68±512.44^*#
F值		1 604.11	163.52	17.24
P值		<0.001	<0.001	<0.001

CKD分期	例数	SCr/（μmol/L）	Cys C/（mg/L）	NT-proBNP/（pg/mL）
CKD1期	18	101.34±26.92	1.01±0.21	675.61±381.73
CKD2~3期	15	345.56±22.83^*	1.64±0.28^*	1 133.17±433.56^*
CKD4~5期	21	626.83±34.05^*#	2.75±0.38^*#	1 525.68±512.44^*#
F值		1 604.11	163.52	17.24
P值		<0.001	<0.001	<0.001

项目	回归系数	P值	HR^①值（95%可信区间）
住院死亡	0.21	<0.001	1.23（1.13~1.45）
出院后30 d死亡	0.11	0.012	1.12（1.08~1.15）
3个月内再住院	0.29	<0.001	1.34（1.30~1.68）

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 11

Related Articles 15

Recommended Articles

Metrics

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.